Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Update on our stategy
View:
Post by VpharmCEO on Jun 30, 2020 2:10pm

Update on our stategy

Please review our update  to shareholders. More to follow next week. Thanks
https://voyageurpharmaceuticals.ca/wp-content/uploads/2020/06/Shareholder-Update-June-30th-2020.pdf
Comment by poppagasket on Jun 30, 2020 2:51pm
thanks
Comment by WarrantOfficer on Jul 01, 2020 10:23am
VpharmCEO, thank you for a Canada Birthday update. It was getting painfully quiet. 
Comment by postie1 on Jul 01, 2020 5:11pm
Thanks for the update. Painfully quiet but patience will be rewarded(imo). I still think that this is a several years story for sure. Research into C60 could mean a decade or more depending on just what is being researched (imo). But I do believe VM is undervalued at this point, so to me it makes for a good long term buy at this price., It is  not  a stock for for traders' that ...more  
Comment by WarrantOfficer on Jul 02, 2020 1:23pm
I am on the same branch as you postie1. This should be a nice growth company over the next 5 years. I am playing on the side of optimisim from the Vpharm CEO post and adding to my position today. 
Voyageur Pharmaceuticals Ltd
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


PRODUCTS PIPELINE CARBON DRUG PROJECT WHITE PAPER CASE STUDIES MANAGEMENT PRESENTATION

Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1